REGENERON PHARMACEUTICALS INC
For the period ended Dec 31, 2024. Filed Feb 5, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 5, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 2. Properties
We conduct our research, development, manufacturing, and administrative activities at our owned and leased facilities. A summary of our significant owned and leased properties is provided below.
| Location | Approximate Square Feet | Use | Leased/Owned |
|---|---|---|---|
| Tarrytown, New York | 1,500,000 | Corporate headquarters, laboratory, and office space | Leased(a) |
| Rensselaer, New York | 1,600,000 | Manufacturing, warehouse, laboratory, fill/finish(b), and office space | Owned |
| Limerick, Ireland | 850,000 | Manufacturing, warehouse, laboratory, and office space | Owned |
| (a) Refer to Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources - Tarrytown, New York Corporate Headquarters Lease" for further details. | |||
| (b) Our fill/finish facility in Rensselaer, New York is currently undergoing process validation as required by regulatory authorities. | |||
In addition to the properties summarized in the table above, we own an approximate 100-acre parcel of land adjacent to our Tarrytown, New York location, which we are in the process of developing, primarily to expand our research, preclinical manufacturing, and support facilities to accommodate our growth. In September 2024, we also acquired an approximate 1,000,000 square foot facility in Saratoga Springs, New York.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.